DEBIOPHARM
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today announced preclinical data releases for two of their compounds inhibiting the DNA-damage response (DDR) of cancer cells, including Debio 0123 [selective WEE1 inhibitor] and Debio 0432 [Selective USP1 Inhibitor] at the 2024 Annual American Association for Cancer Research (AACR) summit in San Diego, California.
“Since 2017, Debiopharm has been growing its expertise in the DDR inhibitor field, firstly through its WEE1-inhibitor Debio 0123 and through the recently in-licensed asset, targeting USP1. These posters are proof of our commitment to stay at the forefront of DDR-inhibitor development and outsmart hard-to-treat cancers through synthetic lethality or other groundbreaking combinations.” - Angela Zubel, Chief Development Officer at Debiopharm
AACR 2024 Poster Presentations |
Debiopharm compound |
Title |
Presenter |
Mon, April 8th
Abstract #: CT064 Poster Section: 48 Poster Board #: 14 |
Debio 0123 |
Impact of food and high gastric pH on the bioavailability of the WEE1 inhibitor Debio 0123 assessed in a Phase 1 dose escalation study |
Anne Bellon, Clinical Pharmacology Lead |
Mon, April 8th
Abstract #: 3370 Poster Section: 29 Poster Board #: 27 |
Debio 0123 |
Anti-tumor activity of Debio 0123 in combination with sacituzumab govitecan in preclinical models of breast cancer |
Luke Piggott, Principal Scientist |
Tue, April 9th
Abstract #: 6507 Poster Section: 46 Poster Board #: 24 |
Debio 0123 |
Simulation driven identification of combination for the WEE1 inhibitor Debio 0123 results in synergistic effect with cabozantinib validated in vivo |
Luke Piggott, Principal Scientist & Turbine AI |
Wed, April 10th
Abstract #: 7145 Poster Section: 23 Poster Board #: 7 |
Debio 0432 |
Identification of Debio 0432 as a potent and selective USP1 inhibitor for cancer therapy |
Noemie Luong, Associate Principal Scientist |
About DNA-Damage Repair (DDR)
When cells have damaged DNA, they need to undergo a repair process called DDR to be able to survive. Cancer cells rely a lot on DDR as they divide and grow uncontrollably. Inhibition of DDR, particularly in combination with other anticancer agents, prevents cancer cells from repairing their DNA, which ultimately activates a self-destruction program in cancer cells. DDR inhibitors such as Debiopharm's WEE1 and USP1 inhibitors, are being tested in clinical and preclinical studies.
Debiopharm’s commitment to cancer patients
Debiopharm aims to develop innovative therapies that target high unmet medical needs in oncology and bacterial infections. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then select large pharmaceutical commercialization partners to maximize patient access globally.
Visit us https://www.debiopharm.com/drug-development/
Follow us @DebiopharmNews
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240404176159/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Digita Selects Netmore Platform-as-a-Service to Scale LoRaWAN®-based IoT Network Capabilities in Finland2.12.2024 08:00:00 CET | Press release
Digita and Netmore to Jointly Develop Large-Scale Projects in Utility, Building, Construction, and Logistics Verticals Netmore Group, a leading global LoRaWAN network operator, today announced that Digita, a Finnish technology company specializing in broadcast networks and telecom services, has selected Netmore’s Operator Platform-as-a-Service (PaaS) to expand, optimize, and scale its LoRaWAN network capabilities for the delivery of Internet of Things (IoT) applications in Finland. The leading domestic network operator, Digita offers a complete infrastructure for IoT services including a nationwide public LoRaWAN network and private network build outs based on customer needs. With an extensive and growing base of digital transformation deployments across the utility, district heating, smart building, and logistics verticals, Digita selected Netmore’s PaaS offering to reduce the number of systems needed to deliver IoT connectivity to its customers. In addition to streamlining its operat
Bureau Veritas completes the acquisition of The APP Group, strengthening its Buildings & Infrastructure leadership position in Asia-Pacific2.12.2024 07:30:00 CET | Press release
Bureau Veritas, a global leader in Testing, Inspection, and Certification services, today announced that it has completed the acquisition of The APP Group, a leading Australian Property and Infrastructure leader, as stated in its communication to the market on November 4th, 2024. The company is headquartered in Sydney and delivered revenues of €87 million in 2023. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241201814044/en/ Hinda Gharbi, CEO Bureau Veritas (Photo: Business Wire) This acquisition is in line with Bureau Veritas’ LEAP | 28 strategy to expand leadership in Buildings and Infrastructure, diversifying its portfolio and investing in an attractive regional market. It will strengthen the Group’s Buildings and Infrastructure capabilities by adding significant project management assistance expertise to asset owners, as well as construction management, independent project verification and certification and benefiting
PQ Expands Nordic Presence with Acquisition of Sibelco's Specialty Silicate Business2.12.2024 06:00:00 CET | Press release
PQ (www.pqcorp.com), a leading global producer of silicates, silicas and derivative products, announced that it has agreed to acquire the specialty silicate business of the Sibelco Group currently operated in the Lödöse plant in Sweden. “Sibelco’s silicate business has a long history of success in Sweden,” said Al Beninati, CEO of PQ. “This acquisition allows PQ to expand our sodium and potassium silicate offerings to the Nordic markets such as mining, construction, and pulp & paper. PQ has operated in the region for over 70 years and looks forward to continuing to provide high-quality products as part of this expanded portfolio.” Completion of the acquisition is subject to customary regulatory approvals and is expected early 2025. About PQ With headquarters in Malvern, Pennsylvania PQ is a leading global provider of silicates, silicas and derivative products. PQ’s products are found in a wide variety of industries and many aspects of everyday life, from decorative paints to green ceme
GE HealthCare to Acquire Remaining 50% Stake in Nihon Medi-Physics (NMP), a Leading Radiopharmaceutical Company in Japan, from Sumitomo Chemical2.12.2024 05:45:00 CET | Press release
GE HealthCare to acquire 50% stake from Sumitomo Chemical to assume full ownership of NMP, subject to regulatory approvals As part of GE HealthCare, NMP, already a leading radiopharmaceutical company in Japan, will enhance patient access to next-generation radiopharmaceuticals that enable detection and diagnosis of disease Acquisition positions NMP to become partner of choice for global innovators looking to bring novel radiopharmaceuticals to Japan and other Asian markets Transaction bolsters GE HealthCare’s Pharmaceutical Diagnostics segment and demonstrates its commitment to shaping the future of Molecular Imaging GE HealthCare (Nasdaq: GEHC) has agreed to acquire full ownership of Nihon Medi-Physics Co., Ltd (NMP), by purchasing from Sumitomo Chemical (TYO: 4005) the 50% stake it does not already own. As part of GE HealthCare, NMP can build on its expertise developing and manufacturing proprietary and in-licensed radiopharmaceuticals used in single photon emission computed tomograp
NetApp Announces Integrated Solution with AWS Outposts for Hybrid Cloud Deployments1.12.2024 20:00:00 CET | Press release
New integration simplifies the use of NetApp block storage with AWS Outposts NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced NetApp on-premises enterprise storage arrays for AWS Outposts, a new integrated solution allowing AWS Outposts customers to simplify the use of external block data volumes running on NetApp on-premises enterprise storage arrays in AWS Outposts deployments directly through the Amazon Web Services (AWS) Management Console. AWS Outposts is a family of fully managed solutions delivering AWS infrastructure and services to virtually any on-premises or edge location for a truly consistent hybrid experience. This solution simplifies hybrid cloud deployments by combining NetApp’s unified data storage and intelligent services with powerful cloud infrastructure offered by AWS Outposts, helping customers optimize cloud deployments on-premises and at the edge. “Whether customers are looking to use hybrid cloud infrastructure to increase re
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom